US Patent

US11103497 — Treatment of imatinib resistant leukemia

Method of Use · Assigned to Wyeth LLC · Expires 2034-02-28 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating a subject with BcrAbl positive leukemia that is resistant to imatinib using 4-anilino-3-quinolinecarbonitriles compounds.

USPTO Abstract

The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3216`	—	bosutinib-monohydrate
`U-3216`	—	bosutinib-monohydrate
`U-3216`	—	bosutinib-monohydrate
`U-3216`	—	bosutinib-monohydrate
`U-3216`	—	bosutinib-monohydrate

Patent Metadata

Patent number: US11103497
Jurisdiction: US
Classification: Method of Use
Expires: 2034-02-28
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.